Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (2919)	4/27/2020 9:06:19 AM
From: Biotechwantabe	Read Replies (1) \| Respond to of 3557

Libtayo news is great. Does anyone know how fast they can get approval?

To: Miljenko Zuanic who wrote (2919)	4/27/2020 10:01:02 AM
From: DewDiligence_on_SI	1 Recommendation Recommended By CuttingEdge Bio Read Replies (2) \| Respond to of 3557

Somehow, regn always report 10-20m over [Bayer's] numbers. The discrepancy stems is from the timing of FX conversions. Converting the full quarter’s sales from euros to dollars at the end of the quarter yields a different result than converting FX continuously throughout the quarter.

To: Miljenko Zuanic who wrote (2919)	4/27/2020 10:10:59 AM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 3557

So, Kevzara (COVID-19) news (https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-provide-update-us-phase-23-adaptive) is hot: -Kevzara did not show benefit in standard severe (low oxygenation) COVID-19 pts... -Subcutaneous Kevzara does not stand the chance, <TARRYTOWN, N.Y. and PARIS, April 27, 2020 /PRNewswire/ -- Independent Data Monitoring Committee recommended continuing ongoing Phase 3 trial only in the more advanced "critical" group with Kevzara higher-dose versus placebo and discontinuing less advanced "severe" group Phase 3 trial will be amended to enroll only "critical" patients Phase 3 trial also be amended to discontinue lower-dose Kevzara (200 mg); all new patients to receive either higher-dose Kevzara (400 mg) or placebo No new safety findings were observed for Kevzara use in COVID-19 patients> And Libtayo (1LNSCLC, PDL1 ++) news ( investor.regeneron.com is not hot: -Cemiplimab is comparable (HR 0.68 v 0.60) to Keytruda, as monotherapy versus chemo, in 1L NSCLC PDL1 positive (+50%), <TARRYTOWN, N.Y. and PARIS, April 27, 2020 /PRNewswire/ -- Libtayo decreased the risk of death by 32.4% compared to chemotherapy Regeneron and Sanofi plan regulatory submissions in 2020>